372 related articles for article (PubMed ID: 9699645)
1. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer.
Hall SJ; Sanford MA; Atkinson G; Chen SH
Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645
[TBL] [Abstract][Full Text] [Related]
2. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice.
Yamamoto S; Suzuki S; Hoshino A; Akimoto M; Shimada T
Cancer Gene Ther; 1997; 4(2):91-6. PubMed ID: 9080117
[TBL] [Abstract][Full Text] [Related]
4. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer.
Nasu Y; Bangma CH; Hull GW; Yang G; Wang J; Shimura S; McCurdy MA; Ebara S; Lee HM; Timme TL; Thompson TC
Prostate Cancer Prostatic Dis; 2001; 4(1):44-55. PubMed ID: 12497062
[TBL] [Abstract][Full Text] [Related]
5. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
7. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer.
Mäkinen K; Loimas S; Wahlfors J; Alhava E; Jänne J
J Gene Med; 2000; 2(5):361-7. PubMed ID: 11045430
[TBL] [Abstract][Full Text] [Related]
10. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
11. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells.
Sanchez-Perez L; Gough M; Qiao J; Thanarajasingam U; Kottke T; Ahmed A; Thompson JM; Maria Diaz R; Vile RG
Gene Ther; 2007 Jul; 14(13):998-1009. PubMed ID: 17443216
[TBL] [Abstract][Full Text] [Related]
12. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
Ren W; Strube R; Zhang X; Chen SY; Huang XF
Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
[TBL] [Abstract][Full Text] [Related]
13. HSV-tk gene therapy for human renal cell carcinoma in nude mice.
Pulkkanen KJ; Parkkinen JJ; Laukkanen JM; Kettunen MI; Tyynela K; Kauppinen RA; Ala-Opas MY; Yla-Herttuala S
Cancer Gene Ther; 2001 Jul; 8(7):529-36. PubMed ID: 11498775
[TBL] [Abstract][Full Text] [Related]
14. [Bystander effect mediated by herpes simplex virus-thymidine kinase/ganciclovir approach on prostatic cancer cells and its regulation].
Xing Y; Lu G; Xiao Y; Zeng F; Zhang Q; Xiong P; Feng W
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1484-7. PubMed ID: 12509912
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir.
Rosenfeld ME; Feng M; Michael SI; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 1995 Dec; 1(12):1571-80. PubMed ID: 9815958
[TBL] [Abstract][Full Text] [Related]
16. [Combined interleukin-2 and herpes simplex virus thymidine kinase gene therapy for head and neck squamous cell carcinoma].
Liu S; Liang C; Yang H; Xian J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):426-9. PubMed ID: 12761956
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.
Eastham JA; Chen SH; Sehgal I; Yang G; Timme TL; Hall SJ; Woo SL; Thompson TC
Hum Gene Ther; 1996 Mar; 7(4):515-23. PubMed ID: 8800746
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
19. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer.
Kagaya T; Nakamoto Y; Sakai Y; Tsuchiyama T; Yagita H; Mukaida N; Kaneko S
Cancer Gene Ther; 2006 Apr; 13(4):357-66. PubMed ID: 16224495
[TBL] [Abstract][Full Text] [Related]
20. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
